Literature DB >> 31837317

The Adaptation and Acceptance of Defocus Incorporated Multiple Segment Lens for Chinese Children.

Yiqiu Lu1, Zhenghua Lin1, Longbo Wen1, Wenyu Gao2, Lun Pan2, Xiaoning Li3, Zhikuan Yang3, Weizhong Lan4.   

Abstract

PURPOSE: We investigated the adaptability and acceptance of a novel spectacle lens design that was recently reported to achieve a significant antimyopia effect.
DESIGN: A prospective, cross-over study.
METHODS: Twenty children were recruited to wear both Defocus Incorporated Multiple Segments (DIMS) and single vision (SV) lens, with a random assignment of which type of lens was experienced first. For each type of lens, high and low contrast central distant visual acuity (VA) and high contrast mid-peripheral near VA were measured at both 500 lux and 50 lux ambient illuminance after 30 minutes' and a week's wearing of the lens. A self-developed questionnaire was applied to evaluate the visual discomfort at the 1-week visit. All quantitative data were analyzed by paired t test, while qualitative data were analyzed with the χ2 or Wilcoxon signed-rank tests.
RESULTS: Central VA was not affected by DIMS lens compared with SV lens in all circumstances (all P > .05). However, the mid-peripheral near VA was found to reduce by approximately 0.06 logarithm of minimal angle of resolution unit in 2 of 4 quadrants (500 lux; P < .05) and in 3 quadrants (50 lux; P < .05) for DIMS lenses. No improvement was detected in the 1-week visit. Mid-peripheral blurred vision was the main visual complaint, which was noticed only once or twice a day. Being aware of the average antimyopic efficacy, 90% of children subjects preferred DIMS lenses.
CONCLUSION: Mid-peripheral vision through DIMS lenses was slightly affected compared with SV lenses. Otherwise, DIMS lenses received good tolerance and acceptance by Chinese children.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31837317     DOI: 10.1016/j.ajo.2019.12.002

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Safety of DIMS Spectacle Lenses and Atropine as Combination Therapy for Myopia Progression.

Authors:  Hakan Kaymak; Ann-Isabel Mattern; Birte Graff; Kai Neller; Achim Langenbucher; Berthold Seitz; Hartmut Schwahn
Journal:  Klin Monbl Augenheilkd       Date:  2022-08-25       Impact factor: 0.742

2.  The impact of spectacle lenses for myopia control on visual functions.

Authors:  Yi Gao; Ee Woon Lim; Adeline Yang; Björn Drobe; Mark A Bullimore
Journal:  Ophthalmic Physiol Opt       Date:  2021-09-16       Impact factor: 3.992

Review 3.  Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia.

Authors:  Sangeethabalasri Pugazhendhi; Balamurali Ambati; Allan A Hunter
Journal:  Clin Ophthalmol       Date:  2020-03-18

4.  The Effects of 0.01% Atropine on Adult Myopes' Contrast Sensitivity.

Authors:  Ziyun Cheng; Jianhui Mei; Suqi Cao; Ran Zhang; Jiawei Zhou; Yuwen Wang
Journal:  Front Neurosci       Date:  2021-02-19       Impact factor: 4.677

Review 5.  [Myopia treatment and prophylaxis with defocus incorporated multiple segments spectacle lenses].

Authors:  Hakan Kaymak; Birte Graff; Kai Neller; Achim Langenbucher; Berthold Seitz; Hartmut Schwahn
Journal:  Ophthalmologe       Date:  2021-07-08       Impact factor: 1.174

6.  Vision tests on spectacle lenses and contact lenses for optical myopia correction: a pilot study.

Authors:  Hakan Kaymak; Kai Neller; Saskia Schütz; Birte Graff; Wolfgang Sickenberger; Achim Langenbucher; Berthold Seitz; Hartmut Schwahn
Journal:  BMJ Open Ophthalmol       Date:  2022-04-05

Review 7.  Overview on Defocus Incorporated Multiple Segments Lenses: A Novel Perspective in Myopia Progression Management.

Authors:  Matteo Mario Carlà; Francesco Boselli; Federico Giannuzzi; Gloria Gambini; Tomaso Caporossi; Umberto De Vico; Alfonso Savastano; Antonio Baldascino; Clara Rizzo; Raphael Kilian; Stanislao Rizzo
Journal:  Vision (Basel)       Date:  2022-04-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.